

Translation

Notice: This document is a translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

May 9, 2025

To Whom It May Concern:

Company Name: Daito Pharmaceutical Co., Ltd.  
Representative: Hiroshi Matsumori, President and CEO  
(Securities Code: 4577, Prime Market of Tokyo Stock Exchange)  
Inquiries: Kenji Otsuga, CFO  
(Telephone Number: +81-76-421-5665)

**Notice Regarding the Status and Completion of Purchase of Own Shares**

(Repurchase of Own Shares under the Provision of the Articles of Incorporation  
Pursuant to Article 459, Paragraph 1 of the Companies Act)

Daito Pharmaceutical Co., Ltd. (the “Company”) hereby announces that the Company repurchased its own shares pursuant to Article 459, Paragraph 1 of the Companies Act of Japan and the provision of the Company’s Articles of Incorporation as detailed below.

This concludes Company's repurchase of its common stock authorized by the Board of Directors' meeting held on January 10, 2025.

- |  |   |
|--|---|
| 1. Class of shares repurchased:        | Common stock                                |
| 2. Total number of shares repurchased: | 10,400 shares                               |
| 3. Total amount of shares repurchased: | 21,503,700 yen                              |
| 4. Repurchase period:                  | From May 1, 2025 to May 9, 2025 *1          |
| 5. Repurchase method:                  | Market purchase on the Tokyo Stock Exchange |

Reference:

1. Outline of the resolution at the Board of Directors’ meeting held on January 10, 2025  
(announced on January 10, 2025)

- |   |   |
|---|---|
| (1) Class of shares to be repurchased:        | Common stock  |
| (2) Total number of shares to be repurchased: | Up to 300,000 shares<br>(Equivalent to 2.0% of the total number of issued shares (excluding treasury shares)) |
| (3) Total amount to be repurchased:           | Up to 700 million yen   |
| (4) Repurchase period:                        | From January 14, 2025 to May 30, 2025 *2  |

2. Cumulative number of own shares repurchased pursuant to the above Board of Directors’ resolution (as of May 9, 2025) \*1

- |   |                 |
|---|-----------------|
| (1) Total number of shares repurchased: | 300,000 shares  |
| (2) Total amount of shares repurchased: | 623,270,200 yen |

\*1 Based on the date of delivery

\*2 Based on the date of contract

End